The Journal of Clinical Oncology (JCO) Publishes Full Results of Disitamab Vedotin in a "Triple-Drug Combination" (RCTS) Regimen for First-Line Gastric Cancer Therapy

2026-06-28

On June 27, the world-renowned oncology journal Journal of Clinical Oncology (JCO) published the full research paper from a Phase II RCTS trial online. The study evaluated the combination of Disitamab Vedotin, Tislelizumab, and S-1 as a first-line th

First Patient In Achieved in RemeGen’s Phase II/III Clinical Study of RC148 in Combination with Chemotherapy as First-Line Therapy for Unresectable or Metastatic Colorectal Cancer

2026-06-15

OnJun 15th, RemeGen (688331.SH/09995.HK) announced that the first patient has been dosed in its Phase II/III clinical study of RC148 (RC148-C303), a novel bispecific antibody independently developed by RemeGen, in combination with chemotherapy as first-li

Remegen's Telitacicept Two Indications Approved on the Same Day, Patients with Sjögren's Syndrome (Dry Disease) and IgA Nephropathy Welcome the World's First Dual-Target Biologic Drug

2026-06-08

On June 8, Remegen (688331.SH/09995.HK) announced that its self-developed global first-in-class BLyS/APRIL dual-target fusion protein innovative drug Telitacicept (RC18) has received approval from the China National Medical Products Administration (NMPA)

2026 EAU | Original Research Findings on Disitamab Vedotin Unveiled: Showcasing Breakthroughs in Urothelial Carcinoma Care

2026-04-17

The Annual European Association of Urology Congress 2026 (EAU Congress 2026), one of the world’s premier urological events, was held in London, the United Kingdom, from March 13 to 16, 2026 (UTC+0). At the congress, results of multiple researches

2026 ASCO-GU | RC48-C017 study update: Disitamab vedotin plus immunotherapy as neoadjuvant treatment delivers lasting survival gains in bladder cancer.

2026-02-28

On February 27 local time, at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) held in San Francisco, USA, the latest efficacy and safety data from the extended follow-up of the phase II clinical study (RC48-C017) o

2026 JPM | Rongchang Biotech: Delivering Innovation at Scale, Solidifying Its Global Competitive Edge for the Future

2026-01-16

On January 15 at 9:00 a.m. local time, Dr. Jianmin Fang, CEO of RemeGen, took the stage at the 44th J.P. Morgan Healthcare Conference in San Francisco—a premier global event for pharmaceutical innovation and investment trends. In his keynote address